Nuvation Bio (NUVB) Expected to Announce Quarterly Earnings on Wednesday

Nuvation Bio (NYSE:NUVB) will likely be posting its Q1 2025 quarterly earnings results after the market closes on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $0.42 million for the quarter.

Nuvation Bio Price Performance

Shares of NYSE NUVB opened at $2.46 on Monday. The firm has a 50-day simple moving average of $1.96 and a two-hundred day simple moving average of $2.37. Nuvation Bio has a 1 year low of $1.54 and a 1 year high of $3.97. The company has a market cap of $833.15 million, a P/E ratio of -1.13 and a beta of 1.42.

Wall Street Analyst Weigh In

NUVB has been the subject of a number of research analyst reports. Citizens Jmp began coverage on shares of Nuvation Bio in a report on Wednesday, April 23rd. They set a “mkt outperform” rating and a $6.00 price objective for the company. Citigroup initiated coverage on Nuvation Bio in a report on Wednesday, April 23rd. They issued an “outperform” rating for the company. Wedbush restated an “outperform” rating and set a $5.00 price objective on shares of Nuvation Bio in a report on Thursday, March 27th. JMP Securities started coverage on Nuvation Bio in a report on Wednesday, April 23rd. They issued a “market outperform” rating and a $6.00 target price for the company. Finally, Royal Bank of Canada restated an “outperform” rating and set a $10.00 price target (up previously from $6.00) on shares of Nuvation Bio in a research note on Tuesday, January 7th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $7.83.

Insider Buying and Selling at Nuvation Bio

In other Nuvation Bio news, CEO David Hung purchased 200,000 shares of Nuvation Bio stock in a transaction dated Friday, April 4th. The shares were acquired at an average cost of $1.66 per share, with a total value of $332,000.00. Following the completion of the transaction, the chief executive officer now owns 58,481,054 shares in the company, valued at approximately $97,078,549.64. This trade represents a 0.34 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 29.93% of the stock is owned by insiders.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.